Summarized by Masters of Longevity from Nature - Main.
Reports detail two deaths in separate Chinese gene-therapy trials and examine regulatory, ethical, and transparency failures implicated in those studies.
Key Takeaways
- A Shanghai company disclosed a child death in a 2025 gene-editing trial and investigators revealed a separate 2024 child death.
- The girl in the reported trial received spinal AAV delivery to treat a CHD3 mutation after toxicology showed liver damage in monkeys.
- Chinese investigator-initiated trial oversight is being tightened and regulatory changes are expected after these incidents.
